Lipres

Quick links to important sections

Lipres

Method of action: Lipid Modifying Agents

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipres

Property Description
Active ingredient Gemfibrozil
Form Oral tablet, film-coated
Pharmacological class Fibrate, Antihyperlipidemic agent
General Purpose Lipid regulation, managing blood fat imbalances
Origin Synthetic compound, fibric acid derivative

What Type of Medicine is Lipres?

Lipres is a prescription-only medication whose active component is Gemfibrozil, a synthetic compound classified as a fibrate, belonging to the larger group of antihyperlipidemic agents. This class of lipid-modifying agents is specifically used for the medical management of abnormal blood fat (lipid) levels. Gemfibrozil is chemically identified as a fibric acid derivative, confirming its specific chemical origin, which has been the subject of pharmacological studies regarding its action profile.


Composition, Form, and Administration

The medication is a single-ingredient product featuring Gemfibrozil as its sole therapeutic substance, formulated as an oral tablet, often film-coated. This format is designed for oral administration, meaning it is intended to be swallowed for systemic absorption. The tablet structure incorporates the active ingredient alongside solid pharmaceutical excipients that form the necessary matrix and coating.


Lipres's Primary Therapeutic Purpose

Lipres functions as a potent lipid regulator that works primarily to normalize the body’s lipoprotein metabolism. Its general purpose is to correct significant imbalances in the blood lipid profile, specifically targeting high concentrations of triglyceride levels and addressing low levels of high-density lipoprotein (HDL) cholesterol. The substance's mechanism of action is clinically recognized for its efficacy in improving lipid metrics. Gemfibrozil is utilized as a treatment option for reducing elevated triglycerides and increasing HDL. The established clinical understanding is that this medication supports the comprehensive management of abnormal blood fat levels.

Regulatory References

  1. Gemfibrozil - LiverTox - NIH Bookshelf

What side effects are possible with Lipres?

Possible Side Effects and Safety Information

Lipres (ezetimibe/simvastatin) is associated with officially documented risks and adverse reactions, primarily related to the statin component (simvastatin). Myopathy, which is muscle pain, tenderness, or weakness, is a common reaction, with the most serious, though rare, form being Rhabdomyolysis. This condition involves muscle breakdown that can lead to acute renal failure and, very rarely, death. The risk of myopathy is dose-related and is higher with the 10 mg/80 mg strength, which is generally restricted to patients who have demonstrated tolerance and benefit on this dose for an extended period.

Clinically significant safety concerns also include persistent elevations in hepatic transaminases, which may be a sign of liver dysfunction. Liver enzyme tests are required before starting treatment and as clinically indicated thereafter. Hypersensitivity reactions, including rare cases of anaphylaxis, have been reported.

Adverse Reaction Categories and Frequency

Classification Examples of Documented Adverse Reactions
Common ( ge 1/100 ) Myalgia, headache, upper respiratory tract infection, diarrhea, elevated liver enzymes.
Uncommon ( ge 1/1,000 to <1/100 ) Abdominal pain, nausea, flatulence, rash, pruritus, insomnia, dizziness, arthralgia, muscle cramps.
Serious / Rare Rhabdomyolysis, Immune-Mediated Necrotizing Myopathy (IMNM), persistent hepatic failure, anaphylaxis.

Safety Restrictions and Monitoring

Lipres is contraindicated in patients with active liver disease or unexplained, persistent elevations in serum transaminases, and during pregnancy and lactation. Dose adjustments and restrictions are necessary when certain medications that inhibit the CYP3A4 enzyme are used concomitantly, as these can significantly increase the risk of myopathy. Predisposing factors for muscle effects include advanced age, female gender, renal impairment, and uncontrolled hypothyroidism. Patients are advised to promptly report any unexplained muscle pain, tenderness, or weakness.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory guidance for Lipres (Gemfibrozil) strictly defines the clinical and physiological manifestations of overdosage and mandates a specific emergency response.

Documented Overdose Manifestations

Overdose presentations, typically following the intake of too many tablets, may involve a cluster of gastrointestinal and musculoskeletal signs:

  • Gastrointestinal effects: Stomach cramps, diarrhoea, and feeling or being sick.
  • Musculoskeletal effects: Joint or muscle pain, tenderness, weakness, or swelling.

Severe Physiological Indicators and Required Action

Overdose is associated with physiological findings that require urgent care. These include laboratory evidence of abnormal liver function tests and increased enzymes in the body. A severe indicator reported is dark-colored urine, which reflects potential myoglobinuria due to significant enzyme elevation.

Required Emergency Action: Upon accidental overdosage, regulatory documents require that you contact a doctor or nearest hospital emergency department immediately for advice. You should also take the patient information leaflet or any remaining tablets.

Overdose Management Constraints: The official guidance confirms that no specific antidote is documented for Gemfibrozil overdose. Management is therefore constrained to the administration of symptomatic supportive measures. No explicit population-specific considerations are noted in the overdose section.

Therapeutic Uses of Lipres

What Lipres Treats: Main Uses and Benefits

The medication is generally employed as adjunctive therapy to diet to manage symptoms related to systemic imbalance in blood fat levels. Lipres is commonly used to help with adult patients who present with very high serum triglyceride concentrations (severe hypertriglyceridemia), and is applied in conditions involving episodic or fluctuating manifestations such as Type IV and Type V hyperlipoproteinemia.

The primary therapeutic area is applied in addressing elevated circulating blood fats, which provides support that helps ease the overall symptom burden and is relevant for easing the heightened systemic burden associated with the potential for acute pancreatitis. The medication may also assist with managing the overall cardiovascular risk profile in specific patient groups with a challenging combination of low HDL cholesterol and elevated triglycerides.

Quick Fact: Support for Severe Triglyceride Elevation

This targeted action can contribute to improved comfort by addressing symptoms related to heightened physiological activity associated with cardiovascular risk in these patient subgroups.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

The official regulatory documents for Lipres (Gemfibrozil) define specific eligibility rules based on age, organ function, and pre-existing conditions.

Populations Who Must Not Use Lipres (Contraindicated)

Lipres is contraindicated and must not be used by patients presenting with severe renal impairment (severe kidney dysfunction) or hepatic dysfunction (active liver disease). The medicine is also prohibited for individuals with known pre-existing gallbladder disease or a history of gallstones (cholelithiasis), and for those with a known hypersensitivity to Gemfibrozil or any of its excipients.

Age-Group and Physiological Restrictions

Use of Lipres is established for adults (individuals 18 years of age and older). However, the safety and efficacy of the medicine have not been established in pediatric patients (those younger than 18 years). Furthermore, Lipres is not recommended during pregnancy or for women who are breastfeeding.

Conditional Use (Caution Required)

The medicine should be used with caution in patients with mild to moderate renal impairment. Older adults (the geriatric population) may also require cautious use due to potential age-related changes in kidney function. Additional caution is advised for patients with uncontrolled hypothyroidism or a history of muscle problems.

What should I know about interactions with other medicines?

The regulatory profile for Lipres (Gemfibrozil) formally contraindicates its co-administration with Simvastatin, Repaglinide, Dasabuvir, and Selexipag due to the officially documented risk of severe interaction outcomes, such as significant increases in systemic drug exposure. Gemfibrozil is classified as a strong CYP2C8 inhibitor and an OATP1B1 inhibitor. This pharmacokinetic interaction mechanism leads to increased plasma concentrations of co-administered drugs that are CYP2C8 substrates or OATP1B1 substrates, often requiring dose reduction of the interacting medicine.

A significant pharmacodynamic interaction involves the additive risk of myopathy and rhabdomyolysis when combined with other agents, specifically HMG-CoA Reductase Inhibitors (Statins) and Colchicine. Gemfibrozil also potentiates the effect of Coumarin Anticoagulants (e.g., Warfarin), necessitating professional monitoring and dose adjustment of the anticoagulant. An administration-timing constraint exists for Bile Acid Sequestrants, which must be taken at least two hours apart from Lipres to prevent interference with its absorption. Consumption of alcohol is noted as interfering with the therapeutic purpose by increasing triglyceride levels. The use of Gemfibrozil is contraindicated in patients with severe hepatic or severe renal impairment due to the documented risk of drug accumulation.

Mechanism of Action

The action of Gemfibrozil (Lipres) is centered on the selective activation of a nuclear transcription factor, the Peroxisome Proliferator-Activated Receptor-alpha (PPAR-alpha). Gemfibrozil acts as a ligand that binds to and activates this receptor, which is expressed predominantly in the liver, muscle, and adipose tissue, thereby modulating the body's processes for fat metabolism.

Genomic Programming and Triglyceride Clearance

Activation of PPAR-alpha results in a genomic cascade that alters protein expression. Specifically, it causes the transcriptional upregulation of Lipoprotein Lipase (LPL) and the downregulation of the inhibitory protein Apolipoprotein C-III (ApoC-III). The resulting enhanced enzyme activity accelerates the catabolism of triglyceride-rich VLDL and chylylomicrons, leading to the enhanced clearance of triglycerides from the plasma.

Stimulation of High-Density Lipoprotein Production

This same PPAR-alpha activation cascade promotes the production of High-Density Lipoprotein (HDL). This is achieved through the transcriptional upregulation of the structural proteins Apolipoprotein A-I and A-II (ApoA-I/A-II), which are essential components of functional HDL particles. The increase in these HDL components contributes to the reverse cholesterol transport mechanism, resulting in the alteration of the circulating lipid profile.

Dosage and Administration Information

How to Use Lipres: Official Administration Guidelines

Lipres (Gemfibrozil) is a medication whose usage is defined by standardized clinical guidelines. These guidelines detail the specific methods, timing, and dosage adjustments that govern its application in clinical practice.


Administration Scope

Instruction Detail
Route of Administration The medication is designed for oral administration as a film-coated tablet.
Standard Dosing Schedule The typical total daily dose for adults is 1200 mg, generally administered in two divided doses.
Timing in Relation to Meals Doses must be taken 30 minutes before both the morning and evening meals to ensure proper systemic absorption.
Special Procedural Conditions Administration must be separated by 2 hours or more from bile acid-binding resins. For individuals with mild to moderate kidney impairment, a reduced starting dose of 900 mg daily is specified.

Procedural Structure and Duration

The official administration protocol requires the 600 mg tablet to be taken twice daily. This defines the standard regimen. Treatment is generally part of a long-term plan, but clinical protocols suggest that efficacy be formally assessed after three months of therapy; if a satisfactory lipid response has not been achieved within this period, the course should be re-evaluated. Dosing for older adults is typically the same as the standard adult regimen, though use in pediatric patients is not generally recommended due to insufficient data. These instructions define the standardized conditions under which the medication is to be administered.

Recent Clinical Evidence

Research evidence / Overview of studies for Lipres (Gemfibrozil)


Research Evidence for Managing Very High Triglycerides

Lipres was studied for its use in managing conditions characterized by very high levels of triglycerides in the blood. Researchers conducted short-term randomized controlled trials and prospective studies exploring short-term changes in lipid levels. Research examined changes in key blood markers that were observed during the study period, including serum triglyceride levels and Very Low-Density Lipoprotein (VLDL) cholesterol. Trials consistently documented measurements indicating shifts in triglyceride and VLDL cholesterol levels. What remains uncertain is the scope of long-term trial data specifically focused on outcomes related to acute complications, such as the prevention of pancreatitis.

Studies on Coronary Heart Disease (CHD) Risk in Specific Patients

The medicine was evaluated in large-scale, long-term, randomized trials to see how it was associated with the occurrence of serious coronary events. Studies reported measurements of a lower occurrence of coronary events in the treatment group compared to the comparison group, which was observed most noticeably in a specific subgroup of patients who started the study with both low HDL cholesterol and high triglycerides. Conversely, a separate trial exploring secondary prevention (in patients who had already experienced a coronary event) reported measurements indicating no difference in the rate of cardiovascular events when compared to a placebo. This suggests that data for certain groups remain inconsistent.

Overview of Lipid Profile Modulation Research

Researchers have conducted numerous studies to describe how this medicine influences the overall balance of blood lipids. Research highlights changes measured during the study period, consistently showing measurements of reductions in triglyceride levels and increases in HDL cholesterol concentrations. Findings regarding Low-Density Lipoprotein (LDL) cholesterol levels were mixed, with some reports noting a temporary rise in LDL in patients with certain forms of hyperlipoproteinemia. Comparative evidence against other lipid-modifying agents in terms of hard cardiovascular outcomes is lacking.

Long-Term Trial Durations and Follow-up Data

The long-term outcomes research was conducted as part of the large primary prevention coronary heart disease trials. The main observation periods for these studies lasted approximately five years. The research base includes post-trial follow-up periods extending up to 18 years that tracked overall mortality in some groups.

Key Studies & References

  1. Gemfibrozil Drug Information (Overview of Uses and Effects)

Frequently Asked Questions (FAQ)

Common questions about Lipres (FAQ)


Q: Is Lipres the same as [similar drug name]?

A: Lipres contains the active ingredient gemfibrozil, which is classified as a fibrate, a type of lipid-modifying agent. This active substance is also available under the brand name Lopid and in generic form. Official regulatory documents classify all these products as containing the same therapeutic agent.


Q: Is it true that Lipres can cause weight gain?

A: Weight changes, including both weight gain and weight loss, have been documented in official reports for fibrates. However, a significant increase in weight is not reported as a common side effect in the core clinical trial data for gemfibrozil. Official patient information notes that weight changes have generally been documented in post-marketing experience rather than as common occurrences.


Q: Does Lipres affect blood sugar levels?

A: While Lipres is used primarily to manage blood fat (lipid) levels, official guidelines emphasize that other medical problems, such like diabetes mellitus, should be managed optimally before beginning this medication. The inclusion of this information in official guidance shows the relevance of managing blood sugar control alongside lipid levels.


Q: Is Lipres known to cause headaches?

A: Yes, regulatory documents and official prescribing information for the active ingredient gemfibrozil list headache as one of the commonly reported side effects. Official documentation notes this as a commonly reported side effect.


Q: Does Lipres have a risk of dependence or withdrawal?

A: Official studies on the active ingredient, gemfibrozil, do not report symptoms of physical dependence or withdrawal syndrome occurring when the medication is stopped suddenly. However, stopping treatment may result in the return of the condition being managed.


Q: Are generic versions of Lipres effective?

A: The active substance, gemfibrozil, is widely available in generic forms. The Food and Drug Administration (FDA) classifies these generic medicines as therapeutically equivalent to the brand-name product. This regulatory designation indicates they are considered therapeutically equivalent to the brand-name product.


Q: Can Lipres affect my sleep?

A: Official regulatory documents list adverse reactions related to the nervous system. These documented side effects include somnolence (drowsiness or feeling sleepy) and insomnia (having trouble sleeping), although they are usually classified as uncommon or rare experiences.


Q: What happens if I miss a dose of Lipres?

A: If a dose is missed, official patient instructions outline specific steps for determining whether to take the dose or skip it to maintain a safe regimen. It is specified that extra medicine must not be taken to compensate for the missed dose.


Q: Can Lipres be cut in half or crushed?

A: The film-coated Lipres tablet is officially described as having a score line. The Summary of Product Characteristics (SmPC) notes that this score line is included to allow the tablet to be broken, which can facilitate swallowing or dividing the dose. The tablet is a film-coated form, and official information relates the score line only to breaking the tablet, not crushing or chewing.


Q: What are the restrictions on using Lipres before surgery?

A: The official product labeling does not contain specific, universal administration instructions regarding stopping the medication prior to common surgical procedures. However, studies have noted a higher occurrence of gallbladder surgery (cholecystectomy) in some patient groups receiving the drug, which is noted as a relevant safety observation in the official documents.


Q: Can Lipres cause changes in mood?

A: Official documents list certain effects related to psychiatric and emotional health. These documented side effects include reports of depression and decreased libido (sex drive) as uncommon or rare documented adverse events associated with the active ingredient.


Q: Does Lipres affect fertility?

A: Official product documentation reports that impotence has been noted as a side effect. While the medicine is not recommended during pregnancy or breastfeeding, information regarding its effects on general fertility in humans is limited in the official labeling.


Q: Can Lipres be taken with coffee or tea?

A: Official drug information for the active ingredient, gemfibrozil, does not list interactions with typical beverages like coffee or tea.


Q: Does Lipres interact with any herbal remedies?

A: Official patient instructions generally advise patients to inform their healthcare provider about all prescription and over-the-counter (OTC) medicines, vitamins, and supplements, including herbal products. Official patient instructions recommend informing a healthcare provider of any herbal products being used.


Q: Is Lipres a controlled substance?

A: No, official U.S. regulatory information confirms that the active ingredient in Lipres, gemfibrozil, is not classified as a controlled substance under federal regulations. The classification confirms its status under federal regulations.

How should Lipres be stored and disposed of?

Storage and Disposal Requirements for Lipres (Gemfibrozil)

Storage & Disposal Entity Official Regulatory Requirement
Storage Temperature Controlled room temperature (20 C to 25 C / 68 F to 77 F), avoiding freezing.
Container & Protection Store in the tightly closed container it came in, protected from light and moisture.
Child Safety Keep out of the reach of children.
Disposal Instructions Dispose of unused product according to local regulations. If a take-back program is unavailable, mix with an undesirable substance before discarding in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipres found in:

A-Z Index: